Abstract
Trilostane is considered an efficacious and safe medication for canine pituitary-dependent hyperadrenocorticism (PDH). Its recommended frequency of administration is once daily. In this prospective study, the efficacy, toxicity, and long-term outcome of trilostane administered twice daily per os were evaluated in 44 dogs with PDH. Mean initial dose was 3.1 mg/kg q 12 hours, and mean final dose was 3.2 mg/kg q 12 hours. The final total daily dose was lower than previously reported for once-daily administration. The mean survival time for affected dogs was 930 days.
MeSH terms
-
Adrenocortical Hyperfunction / diagnosis
-
Adrenocortical Hyperfunction / drug therapy
-
Adrenocortical Hyperfunction / mortality
-
Adrenocortical Hyperfunction / veterinary*
-
Animals
-
Dihydrotestosterone / adverse effects
-
Dihydrotestosterone / analogs & derivatives*
-
Dihydrotestosterone / therapeutic use
-
Dog Diseases / diagnosis
-
Dog Diseases / drug therapy*
-
Dog Diseases / mortality
-
Dogs
-
Enzyme Inhibitors / adverse effects
-
Enzyme Inhibitors / therapeutic use*
-
Female
-
Male
-
Prospective Studies
-
Safety
-
Survival Analysis
-
Treatment Outcome
Substances
-
Enzyme Inhibitors
-
Dihydrotestosterone
-
trilostane